北京中伦(成都)律师事务所 ZHONG LUN 中倫律師事務所 特殊的普通合伙 Limited Liability Partnership 关于 江苏联环药业股份有限公司 2025年第一次临时股东会 的 法律意见书 二〇二五年八月 北京 ・ 上海 ・ 深圳 ・ 广州 ・ 武汉 ・ 成都 ・ 重庆 ・ 青岛 ・ 杭州 ・ 南京 ・ 海口 ・ 东京 ・ 香港 ・ 化改 ・ 招待 ・ 洛杉矶 ・ 阿拉木图 Beijing ・Stanghai・Slenzhen・Grangdov・Wuhan・Chongzhou・Hangzhou・Hangzhou・Haiikou - Idange 法律意见书 北京中伦(成都)律师事务所 关于江苏联环药业股份有限公司 2025 年第一次临时股东会的 法律意见书 致:江苏联环药业股份有限公司 根据《中华人民共和国公司法》(下称"《公司法》")、《上市公司股东 会规则》(以下简称"《股东会规则》")、《律师事务所从事证券法律业务管 理办法》（以下简称"《证券法律业务管理办法》"）、《律师事务所证券法律 业务执业规则(试行)》(以下简称"《证券法律业务执业规则》")等相关法 律、行政法规、规章 ...

New Stock Listings - Tianfu Long (603406) issued at a price of 23.60[1] - Youli Intelligent (920007) issued at a price of 23.99[1] Rights Issues and Announcements - China Heavy Industry (601989) cash option declaration period from August 13, 2025[1] - China Shipbuilding (600150) acquisition request period from August 13 to August 15, 2025[1] - Shenkai Co., Ltd. (002633) offer declaration period from July 29 to August 27, 2025[1] - ST Kelly (300326) offer period from July 17 to August 15, 2025[1] - Fushun Special Steel (600399) offer period from August 12 to September 10, 2025[1] Abnormal Fluctuations - Multiple stocks reported abnormal fluctuations, including *ST Yushun (002289) and Changcheng Military Industry (601606)[2][3] - Notable fluctuations also reported for companies like Li De Man (300289) and Dongjie Intelligent (300486)[3]

Market Overview - On August 8, the chemical pharmaceutical sector rose by 0.24% compared to the previous trading day, with Lianhuan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3635.13, down 0.12%, while the Shenzhen Component Index closed at 11128.67, down 0.26% [1] Stock Performance - Notable declines in individual stocks include: - Shanghai Yizhong: closed at 72.23, down 5.42% with a trading volume of 80,000 shares and a turnover of 573 million yuan - Yifang Bio: closed at 39.80, down 5.37% with a trading volume of 203,000 shares and a turnover of 818 million yuan - Qianhong Pharmaceutical: closed at 10.19, down 4.77% with a trading volume of 1,197,800 shares and a turnover of 1.23 billion yuan [1] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 230 million yuan from institutional investors and a net outflow of 93.16 million yuan from retail investors, while retail investors saw a net inflow of 323 million yuan [1] - Key stocks with significant capital flow include: - Meinuohua: net inflow of 236 million yuan from institutional investors, with a 18.01% share - Lianhuan Pharmaceutical: net inflow of 197 million yuan from institutional investors, with a 13.40% share [2] - Other notable stocks include Han Yu Pharmaceutical and Bo Rui Pharmaceutical, with net inflows of 171 million yuan and 131 million yuan from institutional investors, respectively [2]

Group 1: Import Drug Tariffs - The U.S. President Trump announced plans to impose "small tariffs" on imported drugs, with rates expected to rise to 150% within a year and potentially to 250% thereafter, aiming to encourage domestic production of pharmaceuticals [1] Group 2: National Drug Procurement - The National Healthcare Security Administration reported that 480 companies submitted information for the 11th batch of drug procurement, with an average of 15 companies per drug, and some drugs having over 40 companies competing [2] Group 3: Dongyangguang Changjiang Pharmaceutical - Dongyangguang Changjiang Pharmaceutical voluntarily withdrew its H-share listing in Hong Kong, as its parent company proposed a privatization plan to merge the company, which is expected to enhance operational efficiency and market performance post-merger [3] Group 4: Yibai Pharmaceutical - Yibai Pharmaceutical received a suspension notice from the Guizhou Provincial Drug Administration due to compliance issues found during inspections, specifically related to record-keeping and data reliability [4] Group 5: Lianhuan Pharmaceutical - Lianhuan Pharmaceutical responded to inquiries regarding unusual stock price fluctuations, stating there are no undisclosed significant matters affecting its stock price, and that its LH-1801 project is still in the research phase, which will not significantly impact revenue in the near term [5]

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. experienced significant stock price fluctuations, with a cumulative closing price increase exceeding 20% over three consecutive trading days in early August 2025, prompting an announcement regarding abnormal trading activity [2][3]. Summary by Sections Stock Trading Abnormality - The company's stock price increased by over 20% cumulatively on August 1, 4, and 5, 2025, which is classified as abnormal trading activity according to the Shanghai Stock Exchange rules [2][3]. Company Operations and Major Events - A self-inspection revealed that the company's production and operations are normal, with no significant changes in market conditions or internal operations [4]. - The company confirmed that there are no undisclosed major events, such as asset restructuring or significant transactions, involving its controlling shareholders or actual controllers [5]. Media Reports and Market Rumors - The company found no significant events that could impact its stock price, nor any media reports or market rumors that require clarification [6]. Other Price-Sensitive Information - No other major events that could significantly affect the company's stock price were identified, and there were no stock trading activities by the controlling shareholders or management during the abnormal trading period [7]. Financial Performance - The company expects a net profit loss for the first half of 2025, estimating a range of -45 million to -38 million RMB, representing a decrease of 100.89 million to 107.89 million RMB compared to the same period last year, indicating a shift from profit to loss [2][12].

江苏联环药业股份有限公司 2025 年第一次临时股东会会议资料 江苏联环药业股份有限公司 （股票代码：600513） 会议日期：二〇二五年八月十一日 -1- 江苏联环药业股份有限公司 2025 年第一次临时股东会会议资料 目 录 股东会会议须知·················· ········································- 3 – 联环药业 2025 年第一次临时股东会会议基本情况及议程·······················- 4 - ········································- 6 - 议案一：《关于选举吴方女士为公司独立董事的议案》··························- 7 - 议案二：《关于公司拟发行科技创新债券的议案》······························- 8 - -2- 江苏联环药业股份有限公司 2025 年第一次临时股东会会议资料 股东会会议须知 为维护投资者合法权益，确保公司股东会正常秩序和顺利召开，根据《公司法》、 《上 市公司股东大会规则》及《公司章程》的有关规定，特 ...

证券代码：600513 证券简称：联环药业 公告编号：2025—054 江苏联环药业股份有限公司 股票交易异常波动的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 日、8 月 4 日、8 月 5 日连续三个交易日内收盘价格涨幅偏离值累计超过 20%， 根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动。 控股股东及实际控制人不存在应披露而未披露的重大信息，包括但不限于重大资 产重组、股份发行、重大交易类事项、业务重组、股份回购、破产重整、重大业 务合作、引进战略投资者等重大事项。 -4,500.00 万 元 人 民 币 至 -3,800.00 万 元 人 民 币 ， 与 上 年 同 期 相 比 将 减 少 一、股票交易异常波动的具体情况 公司股票于 2025 年 8 月 1 日、8 月 4 日、8 月 5 日连续三个交易日内收盘价 格涨幅偏离值累计超过 20%，根据《上海证券交易所交易规则》的有关规定，属 于股票交易异常波动。 （一）生产经营情况 经公司自查，公司目前生产经营正常，市场环境、行业 ...

Group 1 - The State Council issued opinions on gradually promoting free preschool education, starting from the autumn semester of 2025, exempting public kindergarten tuition fees for children in their last year [2] - The People's Bank of China and seven departments released guidelines to support new industrialization, focusing on enhancing financial services for emerging industries and promoting multi-level capital market financing [3] - The National Health Commission and 16 departments launched the "Healthy China Action - Healthy Environment Promotion Action Implementation Plan (2025-2030)" to advance the construction of a beautiful and healthy China [3] Group 2 - In July, the China Logistics and Purchasing Federation reported a logistics industry prosperity index of 50.5%, indicating continued expansion in logistics demand despite adverse weather conditions [4] - The China Electromechanical Products Import and Export Chamber opposed unfair competition in the photovoltaic industry, particularly regarding exports below cost [4] - The Shanghai Development and Reform Commission announced that all new energy power generation will participate in market trading by the end of 2025, impacting pricing mechanisms [4] Group 3 - A-share company Upwind New Materials may apply for a continuous suspension of trading if stock prices rise further [6] - Dongjie Intelligent reported no significant changes in production and operations [6] - Muyuan Foods reported a revenue of 11.639 billion yuan from pig sales in July, a year-on-year decrease of 10.41% [6] - Vanke A received a loan of up to 1.681 billion yuan from Shenzhen Metro Group [6] - Ruoyuchen plans to issue H-shares and list on the Hong Kong Stock Exchange [6] - Anker Detection's controlling shareholder changed to Xirui Technology, and the stock resumed trading [6] - Daodaquan's controlling shareholder plans to increase its stake by 50 million to 100 million yuan [6] - Sanjiang Shopping will not renew its cooperation agreement with Hema Fresh after it expires [6] - Yinglian Co. signed a strategic cooperation agreement with a well-known cylindrical battery company [6] - Lianhuan Pharmaceutical's LH-1801 project is not expected to significantly impact revenue and operating performance in the near term [6]

Group 1 - The core point of the article is that Lianhuan Pharmaceutical (600513) announced an abnormal fluctuation in its stock trading, with a cumulative price increase deviation of over 20% in three consecutive trading days [1] - The LH-1801 project is currently in the research and development stage and is not expected to have a significant impact on the company's revenue and operating performance in the foreseeable future [1]

江苏联环药业股份有限公司 江苏联环药业股份有限公司 2025 年第一次临时股东会会议资料 2025 年第一次临时股东会会议资料 （股票代码：600513） 会议日期：二〇二五年八月十一日 - 1 - 江苏联环药业股份有限公司 2025 年第一次临时股东会会议资料 目 录 | 股东会会议须知··························································- – | | 3 | | --- | --- | --- | | 联环药业 年第一次临时股东会会议基本情况及议程·······················- 4 - | 2025 | | | 2025 年第一次临时股东会投票卡···········································- 6 - | | | | 议案一：《关于选举吴方女士为公司独立董事的议案》··························- 7 - | | | | 议案二：《关于公司拟发行科技创新债券的议案》······························- 8 - | | | - 2 - 江苏 ...